Francesco Grossi

21.8k total citations
326 papers, 6.9k citations indexed

About

Francesco Grossi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Francesco Grossi has authored 326 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 217 papers in Oncology, 213 papers in Pulmonary and Respiratory Medicine and 57 papers in Molecular Biology. Recurrent topics in Francesco Grossi's work include Lung Cancer Treatments and Mutations (162 papers), Lung Cancer Research Studies (73 papers) and Cancer Immunotherapy and Biomarkers (67 papers). Francesco Grossi is often cited by papers focused on Lung Cancer Treatments and Mutations (162 papers), Lung Cancer Research Studies (73 papers) and Cancer Immunotherapy and Biomarkers (67 papers). Francesco Grossi collaborates with scholars based in Italy, United States and United Kingdom. Francesco Grossi's co-authors include Erika Rijavec, Carlo Genova, Maria Giovanna Dal Bello, Simona Coco, Angela Alama, Alice Indini, Andrea Ardizzoni, Filippo de Marinis, Federica Biello and Irene Vanni and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Francesco Grossi

317 papers receiving 6.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francesco Grossi Italy 42 3.8k 3.4k 1.8k 1.0k 782 326 6.9k
Jyoti D. Patel United States 38 3.9k 1.0× 3.4k 1.0× 1.4k 0.8× 832 0.8× 495 0.6× 230 6.1k
Baohui Han China 42 3.9k 1.0× 4.6k 1.4× 1.9k 1.1× 1.4k 1.4× 606 0.8× 458 7.7k
James Stevenson United States 38 3.5k 0.9× 2.8k 0.8× 1.2k 0.7× 546 0.5× 568 0.7× 137 5.9k
Åslaug Helland Norway 40 2.7k 0.7× 2.3k 0.7× 2.7k 1.5× 1.8k 1.7× 784 1.0× 190 6.0k
Wilfried Eberhardt Germany 39 4.2k 1.1× 5.3k 1.6× 1.7k 0.9× 892 0.9× 379 0.5× 239 7.6k
Philip Bonomi United States 42 4.9k 1.3× 4.4k 1.3× 2.1k 1.2× 978 0.9× 343 0.4× 241 8.0k
David M. Jackman United States 38 4.9k 1.3× 5.6k 1.7× 2.0k 1.1× 1.7k 1.6× 307 0.4× 87 7.6k
Rogério Lilenbaum United States 33 5.6k 1.5× 5.5k 1.6× 2.1k 1.2× 1.2k 1.2× 322 0.4× 105 8.4k
Kan Yonemori Japan 38 3.8k 1.0× 1.9k 0.6× 1.4k 0.8× 898 0.9× 534 0.7× 392 6.2k
Mark Vincent Canada 38 3.8k 1.0× 3.7k 1.1× 1.5k 0.9× 723 0.7× 236 0.3× 171 6.5k

Countries citing papers authored by Francesco Grossi

Since Specialization
Citations

This map shows the geographic impact of Francesco Grossi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Grossi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Grossi more than expected).

Fields of papers citing papers by Francesco Grossi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Grossi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Grossi. The network helps show where Francesco Grossi may publish in the future.

Co-authorship network of co-authors of Francesco Grossi

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Grossi. A scholar is included among the top collaborators of Francesco Grossi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Grossi. Francesco Grossi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iaculli, Alessandro, Michele Ghidini, Francesco Locati, et al.. (2024). Multidisciplinary management of immunotherapy‐related adverse events in solid tumors: An inter‐institutional and telemedicine‐based working team. Cancer Medicine. 13(13). e7403–e7403. 5 indexed citations
2.
Bauckneht, Matteo, Carlo Genova, Giovanni Rossi, et al.. (2021). The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. Cancers. 13(13). 3117–3117. 20 indexed citations
3.
Indini, Alice, Erika Rijavec, & Francesco Grossi. (2021). Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. International Journal of Molecular Sciences. 22(9). 4774–4774. 84 indexed citations
4.
Ghidini, Michele, Alice Indini, Erika Rijavec, et al.. (2021). The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. Viruses. 13(3). 508–508. 1 indexed citations
5.
Genova, Carlo, Giovanni Rossi, Marco Tagliamento, et al.. (2020). Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. Expert Review of Respiratory Medicine. 14(4). 367–383. 21 indexed citations
6.
Bonaventura, Aldo, Francesco Grossi, Federico Carbone, et al.. (2020). Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. Clinical & Translational Oncology. 22(9). 1603–1610. 4 indexed citations
7.
8.
Indini, Alice, Fausto Petrelli, Gianluca Tomasello, et al.. (2020). Impact of Use of Gastric-Acid Suppressants and Oral Anticancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. Preprints.org. 4 indexed citations
9.
Pesce, Silvia, Marco Greppi, Francesco Grossi, et al.. (2019). PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. Frontiers in Immunology. 10. 1242–1242. 137 indexed citations
10.
Alama, Angela, Simona Coco, Carlo Genova, et al.. (2019). Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Medicine. 8(7). 1011–1011. 45 indexed citations
11.
Coco, Simona, Silvia Bonfiglio, Davide Cittaro, et al.. (2019). Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. Cancers. 11(4). 441–441. 3 indexed citations
12.
Tagliamento, Marco, Francesco Grossi, Sabrina Paolino, et al.. (2019). Nivolumab Treatment in Advanced Lung Cancer Patient With Chronic Active Hepatitis C and Systemic Lupus Erythematosus. Immunotherapy. 11(10). 873–879. 11 indexed citations
13.
Bonaventura, Aldo, Francesco Grossi, Federico Carbone, et al.. (2019). Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. Cancer Immunology Immunotherapy. 68(8). 1351–1358. 28 indexed citations
14.
Tagliamento, Marco, Carlo Genova, Erika Rijavec, et al.. (2018). Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opinion on Pharmacotherapy. 19(18). 2055–2062. 27 indexed citations
15.
Rossi, Giovanni, Angela Alama, Carlo Genova, et al.. (2018). The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy. 19(17). 1969–1976. 17 indexed citations
16.
Vanni, Irene, Angela Alama, Francesco Grossi, Maria Giovanna Dal Bello, & Simona Coco. (2017). Exosomes: a new horizon in lung cancer. Drug Discovery Today. 22(6). 927–936. 89 indexed citations
17.
Vanni, Irene, Simona Coco, Anna Truini, et al.. (2015). Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform. International Journal of Molecular Sciences. 16(12). 28765–28782. 33 indexed citations
18.
Coco, Simona, Anna Truini, Angela Alama, et al.. (2014). Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Targeted Oncology. 10(3). 393–404. 35 indexed citations
19.
Cappuzzo, Federico, Giovanna Finocchiaro, Francesco Grossi, et al.. (2014). Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(4). 665–672. 22 indexed citations
20.
Cherin, Marco, Nicoletta Buratti, Francesco Grossi, et al.. (2012). Multidisciplinary study of a new Quaternary mammal-bearing site from Ellera di Corciano (central Umbria, Italy): preliminary data. CINECA IRIS Institutial research information system (University of Pisa). 21. 1075–1077. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jyoti D. Patel Breakdown of academic impact, for papers by Baohui Han Breakdown of academic impact, for papers by James Stevenson Breakdown of academic impact, for papers by Åslaug Helland Breakdown of academic impact, for papers by Wilfried Eberhardt Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by David M. Jackman Breakdown of academic impact, for papers by Rogério Lilenbaum Breakdown of academic impact, for papers by Kan Yonemori Breakdown of academic impact, for papers by Mark Vincent
Rankless by CCL
2026